← Leaderboards
Ankur Sheel
Univ Of Massachusetts Med Sch Worcester
$123,149
Attributed
$123,149
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $47.2K · FY2018–20$50K$37.5K$25K$12.5K$0
'18
'19
'20
Funding mix
By agency
NIH$123,149 · 1
By mechanism
F30$123,149 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Haley E Melikian$10,999,129
- Charles G Sagerstrom$13,147,065
- David G Lambright$8,969,021
- Claudio Punzo$4,755,298
- Stephen Jones$8,264,263
Others in their field
Other Emerging Leaders on “Accounting”
- Martha Hering · Westat, Inc.$57,098,843
- John Hobbs · Suny At Stony Brook$41,239,084
- Christopher Bee · Suny At Stony Brook$41,239,084
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Pamela Winer Goldberg · Medical Device Innovation Consortium$28,780,000
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
Research focus
AccountingActive SitesAlternative TherapiesAlternative TreatmentAntitumor EffectBaseBindingBinding SitesBypassCancer CellCancer EtiologyCancer ModelCancer TherapyCell DivisionCell GrowthCell ProliferationCessation Of LifeC-Myc GenesCrispr/Cas TechnologyDoxycyclineExhibitsFamilyFuture3&Apos
Grant awards (3)
Exploiting RNAi-based silencing of Myc and metabolic vulnerabilities to prevent relapse after Kras inhibition in lung cancer$47,195
F30 · FY2020 · CA · contact PI
Exploiting RNAi-based silencing of Myc and metabolic vulnerabilities to prevent relapse after Kras inhibition in lung cancer$46,691
F30 · FY2019 · CA · contact PI
Exploiting RNAi-based silencing of Myc and metabolic vulnerabilities to prevent relapse after Kras inhibition in lung cancer$29,263
F30 · FY2018 · CA · contact PI